Cadila Healthcare Ltd, incorporated in the year 1995, is a Large Cap company with a market cap of Rs 59182.56 Crore, operating in Pharmaceuticals sector.
Cadila Healthcare’s key Products/Revenue Segments include Pharmaceutical Products, Other Operating Revenue and Export Incentives for the year ending 31-Mar-2020.
Investment Rationale
Cadila Healthcare (CDH) received Restricted Emergency Use approval from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN), in treating moderate Covid-19 infections.
Considering the drug’s potential in reducing the need for supplemental oxygen and its better efficacy against other viral infections, Motilal Oswal expects sales of Rs 2.5–3 billion on an annualized basis.
Financials
For the quarter ended 31-12-2020, the company has reported a Consolidated Total Income of Rs 3823.10 Crore, down 0.63 per cent from last quarter’s Total Income of Rs 3847.50 Crore and up 4.51 per cent from last year same quarter’s Total Income of Rs 3658.20 Crore. Company has reported net profit after tax of Rs 512.50 Crore in latest quarter.
Promoter/FII Holdings
Promoters held 74.9 per cent stake in the company as of Dec 30, 2020, while FIIs held 5.2 per cent, DIIs 11.9 per cent and public and other 8 per cent.
